Skip to main navigation
Skip to main content
Skip to Footer
Google Tag Manager
US
Novartis site directory
Our Products
US Products By Brand
Product Portfolio
Our Process
Therapeutic Areas
Patient Assistance
Product Related Issues
About Us
Who We Are
Diversity and Inclusion
Our Leadership
Supplier Diversity
Research
Contact Us
Corporate Responsibility
Novartis in Society US Reports
Corporate Citizenship
Business Conduct
Corporate Integrity Agreement
Payments to Healthcare Professionals
Payments to Healthcare Organizations
Physician Payments - Sunshine Act
Post-Marketing Commitments
Enhanced Verification Request
News
News Archive
Statements
Stories
US Media Contacts
Novartis US COVID-19 Initiatives
Careers
Careers Search
Working at Novartis
Employee Benefits
Awards & Recognition
NIBR Careers Frequently Asked Questions
Search
News Archive
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Media Releases
Stories
Filter By
2020
October
Media Release
/
Oct 05, 2020
Novartis STEP Program™ awards nearly $375,000 to patient advocacy organizations for their innovative solutions in biomarker testing; now accepting proposals for caregiving in cancer and certain blood disorders
Read More
Media Release
/
Oct 03, 2020
Novartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraine
Read More
April
Media Release
/
Apr 03, 2020
Novartis and the Novartis US Foundation establish USD 5 million US COVID-19 Community Response Fund
Read More
September
Media Release
/
Sep 16, 2020
Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
Read More
Media Release
/
Sep 11, 2020
Novartis presents data at ACTRIMS-ECTRIMS on the effects of treatment with Mayzent® (siponimod) studied on disability progression and cognitive processing speed in patients with progressing relapsing multiple sclerosis
Read More
Media Release
/
Sep 11, 2020
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
Read More
August
Media Release
/
Aug 30, 2020
Novartis PARALLAX data provides further evidence of the potential benefit of Entresto® in patients with HFpEF
Read More
Search Results Navigation
Current page
1
of 5
Page
2
of 5
Page
3
of 5
Page
4
of 5
Page
5
of 5
…
Next page
next ›
Last page
last »
Share
Email
Jump to Comments
Print
Save
Related Links
Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative
You are here
Home
›
News
